Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
January 19, 2024
Independent data monitoring committees help to ensure patient safety and uphold trial integrity. In Central Nervous...
Read article
June 9, 2023
Maximizing Study Momentum: A Case Study in Accelerated DMC Safety Report Creation through IDMC Solutions
In the ever-evolving landscape of clinical development, the need for robust evaluation of interim clinical data through...
Read article
March 18, 2022
The Fundamentals of Real World Evidence in Oncology Drug Development
Real world evidence (RWE) provides a large and growing source of insights into drug uptake and safety. It is...
Read article
October 27, 2021
Leveraging Staged Investment Strategy for Funding Novel Therapies
A staged investment strategy aligns R&D decisions and financial planning with the interim looks of a clinical trial. If...
Read article
October 20, 2021
Strategic Clinical Trial Design Unlocks Innovative Opportunity
For health innovators, trial selection is a key success factor as there are no second chances. But how do you find the...
Read article
August 18, 2021
What does reducing the risk of a faulty conclusion mean: Case study
During the design of a clinical trial, many biotechs want to substantially reduce the risk of a good new therapy being...
Read article
July 28, 2021
Lessons Learned from Leveraging Computing Power for Clinical Strategy
“We found an optimal design in hours that might have taken months to find using standard methods,” reflected Fabien...
Read article
July 22, 2021
The Risk of Under-exploring Trial Design Options: A New Case Study
Earlier this year, Cytel founder Cyrus Mehta observed that clinical trial design is often treated like an art rather...
Read article
May 17, 2017
Case Study: From Trial Design to CDISC Submission
This new case study shares how Cytel supported a specialist biopharmaceutical company from Phase 2 trial design through...
Read article
March 24, 2017
Case Study: Improving Go/No-go Decision-Making with Custom Software
Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early...
Read article
November 18, 2016
Case Study: Dose-response modeling informs Phase 2 ulcerative colitis study design
Challenge Our client had the following key questions which they wanted our pharmacometrics group to address for an...
Read article
September 4, 2015
Using Simulation for Accelerated Early Phase Drug Development
Our Client's Challenge: Can knowledge of the relationship between biomarkers and clinical endpoints help us to optimize...
Read article
January 22, 2015
Adaptive Clinical Trial Strategies for the Limited Early Phase Budget
The Journal of the American Medical Association recently published an article entitled ‘The Anatomy of Medical...
Read article